［1］JIANG Q,YANG G,XIAO F,et al.Role of Th22 cells in the pathogenesis of autoimmune diseases［J］.Frontiers in Immunology,2021,12:688066.
［2］PLANK MW,KAIKO GE,MALTBY S,et al.Th22 cells form a distinct Th lineage from Th17 cells in vitro with unique transcriptional properties and Tbet-dependent Th1 plasticity［J］.Journal of Immunology（Baltimore,Md.1950),2017,198(5):2182-2190.
［3］PAN Y,DU D,WANG L,et al.The role of T helper 22 cells in dermatological disorders［J］.Frontiers in Immunology,2022,13:911546.
［4］BARNES JL,PLANK MW,ASQUITH K,et al.T-helper 22 cells develop as a distinct lineage from Th17 cells during bacterial infection and phenotypic stability is regulated by T-bet［J］.Mucosal Immunology,2021,14(5):1077-1087.
［5］KRAGSTRUP TW,ANDERSEN T,HEFTDAL LD,et al.The IL-20 ctokine fmily in reumatoid arthritis and spondyloarthritis［J］.Frontiers in Immunology,2018,9:2226.
［6］JIANG R,SUN B.IL-22 signaling in the tumor microenvironment［J］.Advances in Experimental Medicine and Biology,2021,1290:81-88.
［7］FU D,SONG X,HU H,et al.Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis［J］.Molecular Medicine Reports,2016,13(6):4606-4612.
［8］ZENG C,SHAO Z,WEI Z,et al.The NOTCH-HES-1 axis is involved in promoting Th22 cell differentiation［J］.Cellular & Molecular Biology Letters,2021,26(1):7.
［9］JIAO Q,QIAN Q,LIU C,et al.T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T-cell costimulator［J］.The British Journal of Dermatology,2020,182(3):648-657.
［10］PICCINNI MP,LOMBARDELLI L,LOGIODICE F,et al.Medroxyprogesterone acetate decreases Th1,Th17,and increases Th22 responses via AHR signaling which could affect susceptibility to infections and inflammatory disease［J］.Frontiers in Immunology,2019,10:642.
［11］YESTE A,MASCANFRONI ID,NADEAU M,et al.IL-21 induces IL-22 production in CD4+T cells［J］.Nature Communications,2014,5:3753.
［12］NIU Y,YE L,PENG W,et al.IL-26 promotes the pathogenesis of malignant pleural effusion by enhancing CD4+IL-22+T-cell differentiation and inhibiting CD8+T-cell cytotoxicity［J］.Journal of Leukocyte Biology,2021,110(1):39-52.
［13］GOWHARI SHABGAH A,ABDELBASSET WK,SULAIMAN RAHMAN H,et al.A comprehensive review of IL-26 to pave a new way for a profound understanding of the pathobiology of cancer,inflammatory diseases and infections［J］.Immunology,2022,165(1):44-60.
［14］ROBB CT,MCSORLEY HJ,LEE J,et al.Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis［J］.The Journal of Allergy and Clinical Immunology,2018,141(1):152-162.
［15］WILKINSON AN,CHANG K,KUNS RD,et al.IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling［J］.Blood,2019,134(23):2092-2106.
［16］KORENFELD D,GORVEL L,MUNK A,et al.A type of human skin dendritic cell marked by CD5 is associated with the development of inflammatory skin disease［J］.JCI insight,2017,2(18):e96101.
［17］YANG J,YANG X,WANG L,et al.B cells control lupus autoimmunity by inhibiting Th17 and promoting Th22 cells［J］.Cell Death & Disease,2020,11(3):164.
［18］刘双娇,张艳彬,孟伟,等.沙利度胺联合低剂量地西他滨治疗骨髓增生异常综合征疗效及对患者Th17和Th22细胞水平的影响［J］.药物流行病学杂志,2018,27(9):594-598.
LIU SJ，ZHANG YB，MENG W,et al.Curative effect of thalidomide combined with low-dose decitabine in the treatment of myelodysplastic syndrome and its influence to Th17 cell and Th22 cell［J］.Journal of Pharmacoepidemiology,2018,27(9):594-598.
［19］孙黎黎.沙利度胺联合低剂量地西他滨治疗骨髓增生异常综合征疗效及对Th17和Th22细胞水平的影响［J］.当代医学,2021,27(9):77-79.
SUN LL.Thalidomide combined with low-dose decitabine in the treatment of myelodysplastic syndrome and its effect on Th17 and Th22 cell levels［J］.Contemporary Medicine,2021,27(9):77-79.
［20］SHAO L,ZHANG L,HOU Y,et al.Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome［J］.PLoS One,2012,7(12):e51339.
［21］RAUNDHAL M,GHOSH S,MYERS SA,et al.Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias［J］.Nature Immunology,2021,22(4):520-529.
［22］GHOSH S,RAUNDHAL M,MYERS SA,et al.Identification of RIOK2 as a master regulator of human blood cell development［J］.Nature immunology,2022,23(1):109-121.
［23］YU S,LIU C,ZHANG L,et al.Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia［J］.International Journal of Molecular Sciences,2014,15(2):1927-1945.
［24］张琛.骨髓交感神经及免疫失衡在急性白血病发生发展中的作用研究［D］.济南：山东大学,2020.
ZHANG C.Study on the role of bone marrow sympathetic nerve and imbalance in the development of acute leukemia［D］.Jinan:Shandong University，2020.
［25］TIAN T,SUN Y,LI M,et al.Increased Th22 cells as well as Th17 cells in patients with adult T-cell acute lymphoblastic leukemia［J］.Clinica Chimica Acta,International Journal of Clinical Chemistry,2013,426:108-113.
［26］TIAN T,YU S,LIU L,et al.The profile of T helper subsets in bone marrow microenvironment is distinct for different stages of acute myeloid leukemia patients and chemotherapy partly ameliorates these variations［J］.PLoS One,2015,10(7):e0131761.
［27］SUN Y,KONG H,LIU C,et al.The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia［J］.Human Immunology,2014,75(2):113-118.
［28］CHENG RH.Expression level of Th22 cells and its cytokines in patients with acute lymphoblastic leukemia and its significance［J］.Journal of Experimental Hematology,2013,21(4):857-860.
［29］CHEN P,WANG M,LI D,et al.The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia［J］.Journal of Immunology Research,2015,2015:416123.
［30］GANGEMI S,ALLEGRA A,ALONCI A,et al.Interleukin 22 is increased and correlated with CD38 expression in patients with B-chronic lymphocytic leukemia［J］.Blood Cells,Molecules & Diseases,2013,50(1):39-40.
［31］KOUZEGARAN S,SIROOSBAKHT S,FARSAD BF,et al.Elevated IL-17A and IL-22 regulate expression of inducible CD38 and Zap-70 in chronic lymphocytic leukemia［J］.Clinical Cytometry,2018,94(1):143-147.
［32］LIU Q,HUA M,YAN S,et al.Immunorelated gene polymorphisms associated with acute myeloid leukemia［J］.Clinical and experimental Immunology,2020,201(3):266-278.
［33］中华医学会血液学分会白血病淋巴瘤学组.中国成人急性髓系白血病（非急性早幼粒细胞白血病）诊疗指南（2021年版）［J］.中华血液学杂志,2021,42(8):617-623.
Leukemia & Lymphoma Group,Chinese Society of Hematology,Chinese Medical Association.Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia（not APL）（2021）［J］.Chin J Hematol,2021,42(8):617-623.
［34］LU T,LIU Y,YU S,et al.Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma［J］.Oncotarget,2016,7(35):56574-56583.
［35］BARD JD,GELEBART P,ANAND M,et al.Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma［J］.Leukemia,2008,22(8):1595-1603.
［36］GELEBART P,ZAK Z,DIEN-BARD J,et al.Interleukin 22 signaling promotes cell growth in mantle cell lymphoma［J］.Translational Oncology,2011,4(1):9-19.
［37］PRUTSCH N,GURNHOFER E,SUSKE T,et al.Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma［J］.Leukemia,2019,33(3):696-709.
［38］DI LULLO G,MARCATTI M,HELTAI S,et al.Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival［J］.Oncoimmunology,2015,4(5):e1005460.
［39］WANG M,CHEN P,JIA Y,et al.Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma［J］.Oncotarget,2015,6(20):17958-17967.
［40］TSIRAKIS G,PAPPA CA,KOLOVOU A,et al.Clinical significance of interleukin-22 in multiple myeloma［J］.Hematology（Amsterdam,Netherlands),2015,20(3):143-147.
［41］DI LULLO G,MARCATTI M,PROTTI MP.Non-redundant roles for Th17 and Th22 cells in multiple myeloma clinical correlates［J］.Oncoimmunology,2016,5(4):e1093278.
［42］HOLSTEIN SA,MCCARTHY PL.Immunomodulatory drugs in multiple myeloma:Mechanisms of action and clinical experience［J］.Drugs,2017,77(5):505-520.
［43］OUYANG W,O'GARRA A.IL-10 family cytokines IL-10 and IL-22:from basic science to clinical translation［J］.Immunity,2019,50(4):871-891.
［44］JIN M,YOON J.From bench to clinic:the potential of therapeutic targeting of the IL-22 signaling pathway in atopic dermatitis［J］.Immune Network,2018,18(6):e42.
［45］SABAT R,OUYANG W,WOLK K.Therapeutic opportunities of the IL-22-IL-22R1 system［J］.Drug Discovery,2014,13(1):21-38.
［46］ZENEWICZ LA.IL-22 binding protein（IL-22BP) in the regulation of IL-22 biology［J］.Frontiers in Immunology,2021,12:766586.
［47］ZHANG R,MEN K,ZHANG X,et al.Delivery of a modified mRNA encoding IL-22 binding protein（IL-22BP) for colon cancer gene therapy［J］.Journal of Biomedical Nanotechnology,2018,14(7):1239-1251.
［48］LCKE J,SABIHI M,ZHANG T,et al.The good and the bad about separation anxiety:roles of IL-22 and IL-22BP in liver pathologies［J］.Seminars in Immunopathology,2021,43(4):591-607.
［49］VOIGT C,MAY P,GOTTSCHLICH A,et al.Cancer cells induce interleukin-22 production from memory CD4+T cells via interleukin-1 to promote tumor growth［J］.Proceedings of the National Academy of Sciences of the United States of America,2017,114(49):12994-12999.
［50］ZHANG J,LIU Z,LIU L,et al.Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3［J］.Cytotechnology,2022,74(2):203-216.
［51］LI W,JIANG H,BAI C,et al.Ac2-26 attenuates hepatic ischemia-reperfusion injury in mice via regulating IL-22/IL-22R1/STAT3 signaling［J］.Peer J,2022,10:e14086.
［52］LAU YTK,RAMAIYER M,JOHNSON DE,et al.Targeting STAT3 in cancer with nucleotide therapeutics［J］.Cancers,2019,11(11):1681.